thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),
…
thassodotcom
Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Pharmacogenetics, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
April 07, 2019 – Consumers are increasingly embracing genetic testing to better understand their individual risk for developing diseases. With this rise in popularity and availability, we’re also seeing significant activity in the field of pharmacogenetics, which is the process of understanding what, if any, role genetics plays in a patient’s reaction to particular drugs,
…
thassodotcom
Posted in New Drug Approval, Regulatory Approval, Thasso Post, Theragenomic Medicine
No Comments ↓
March 31, 2019 – The American Food and Drug Administration (FDA) has just approved drugs for two rather problematic neurological conditions, namely multiple sclerosis (i.e., Cladribine (Mavenclad)) and non-radiographic axial spondyloarthritis (i.e., Certolizumab pegol (Cimzia)), offering patients with these conditions urgently need additional therapy options. FDA approves new oral treatment for multiple sclerosis
The FDA approved Cladribine (Mavenclad) tablets to treat relapsing forms of multiple sclerosis (MS ) in adults,
…
thassodotcom
Posted in Genetic Predisposition, Genetic Susceptibility, Thasso Post, Theragenomic Medicine
No Comments ↓
March 13, 2019 – Playing professional soccer; that is the ultimate dream of boys (and more and more girls too) all over the world, except, possibly, for boys in the US, where American Football and/or Baseball may be more prominently in the heads and dreams of boys.
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
February 17, 2019 – The unfortunate recognition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a very rare form of a T-cell lymphoma, gains more momentum by the day. This is actually very positive a development, because it helps women who are getting breast implants for whatever reasons to better known associated health risks,
…
thassodotcom
Posted in New Drug Approval, Rare Diseases, Thasso Post, Theragenomic Medicine
2 Comments ↓
February 07, 2019 – The American Food and Drug Administration (FDA) just approved Caplacizumab-yhdp (Cablivi), the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP),
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
February 02, 2019 – This is potential alarming news for millions of patients worldwide suffering from high blood pressure: Health Canada has just completed a safety review of hydrochlorothiazide and has found that prolonged use of the drug could increase a person’s risk for non-melanoma skin cancer.
…
thassodotcom
Posted in Drug/Drug Interaction, Genetic Background, New Research, Pharmacogenetics, Thasso Post, Theragenomic Medicine
No Comments ↓
January 26, 2019 – Pharmacogenomic approaches are increasingly revealing newly identified genes and genetic variants that are at the base of remarkable inter-individual pharmacokinetic and pharmacodynamic variation of novel direct oral anticoagulants (DOAC).
…
As the person behind thasso.com and the writer of some of the posts to be found on thasso post,
…
Optional: Social Subscribe/Login
thasso: recent comments